NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal (Committee C) meeting minutes

**Minutes:** Confirmed

**Date:** Tuesday 12 January 2021

**Location:** Via Zoom

# Committee members present

1. Professor Steve O’Brien [Chair] Present for all items
2. Dr Peter Selby [Vice Chair] Present for all items
3. Michael Chambers Present for all items
4. Dr David Foreman Present for all items
5. Dr Robert Forsyth Present for all items
6. John Hampson Present for all items
7. Dr Nigel Langford Present for all items
8. Dr Andrea Manca Present for all items
9. Iain McGowan Present for all items
10. Kirandip Moyo Present for all items
11. Dr Mudasar Mushtaq Present for all items
12. Dr Richard Nicholas Present for all items
13. Stella O’Brien Present for all items
14. Professor Subhash Pokhrel Present for all items
15. Professor Andrew Renehan Present for all items
16. Professor Matthew Stevenson Present for all items
17. Dr Paul Tappenden Present for all items
18. Dr Derek Ward Present for all items

# NICE staff present:

Ross Dent, Associate Director Present for all items

Natalie Spray, Programme Manager Present items 1 to 2.3

Gavin Kenny, Project Manager Present for all items

Alex Filby, Technical Adviser Present for all items

Anita Sangha, Technical Analyst Present for all items

Mira Patel, Coordinator, COT Present for all items

Gemma Smith, Coordinator, COT Present for all items

Catherine Pank, Coordinator, MIP Present for all items 1 to 2.3

Pratit Shah, Administrator, TA Present for all items

# External group representatives present:

Samantha Barton, BMJ Group Present for items 1 to 2.3

Tracey Jhita, BMJ Group Present for items 1 to 3

# Professional experts present:

Dr Peter Clark, CDF Clinical Lead, NHS England, Present for all items

# NICE Observers present:

Sarah Blagden, Public Heath Registrar, Central Leadership, Present for all items

Jean Isaac, Technical Analyst, Diagnostics, Present for all items

Ella Livingstone, Technical Adviser, Commercial Risk Assessment, Present for all items

Gareth Murphy, Business Analyst, Resource impact assessment, Present for all items

Ria Skelton, Senior Medical Editor, Publishing, Present for all items

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. Appraisal of Carfilzomib with dexamethasone and lenalidomide for treating multiple myeloma after at least 1 previous therapy [ID1493]
   1. **Part 1 – Open session**
      1. The chair welcomed the invited professional experts, external group representatives, members of the public and company representatives from Amgen UK.
      2. The chair asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Richard Nicolas declared financial interests as he has been a PI on trials and attended paid advisory boards for Novartis in an unrelated area.
* It was agreed that Richards declaration would not prevent him from participating in this section of the meeting.
* Prithwiraj Das declared non-financial professional & personal Interests as he recently worked until 31/12/2020 as the Market Access Lead for Specialty Medicines [Oncology, Inflammation, Thrombolysis] Boehringer Ingelheim Ltd. From 18/01/2021 he will have start new employment with a different pharmaceutical company, neither the manufacturer, nor the comparator in both the scheduled assessments for this committee meeting.
* It was agreed that Prithwiraj declaration would not prevent him from participating in this section of the meeting.
* No further conflicts were declared for this appraisal.
  1. The Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] or Final Appraisal Document [FAD] received from consultees, commentators and through the NICE website.
  2. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
  3. **Part 2 – Closed session [company representatives, professional experts, external group representatives and members of the public were asked to leave the meeting]**
     1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus..
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

1. Date of the next meeting

The next meeting of the Technology Appraisal (Committee C) will be held on Wednesday 10 March 2021 and will start promptly at 09:30am.